

Company Beximco Pharmaceuticals Ltd
TIDM BXP
Headline Stock Dividend Issued
Released 09:11 23-Jun-2010
Number 0918009

RNS Number : 09180
Beximco Pharmaceuticals Ltd
23 June 2010

BEXIMCO PHARMACEUTICALS LTD.

23 June, 2010

Stock Dividend Issued

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) announces that the stock dividend proposed on 29 April 2010 and passed by shareholders at the Annual General Meeting on 15 June 2010 has today been credited to shareholder accounts.

The Company has applied for admission of the GDRs issued in respect of the stock dividend to be admitted to trading on the London Stock Exchange's AIM market and admission is expected to occur on or around 28 June 2010.

Following admission, the total issued share capital of the Company will be 209,806,509 ordinary shares of Taka 10 ("Ordinary Shares"), of which 47,047,866 will be represented by GDRs, each representing one Ordinary Share of Taka 10. The new Ordinary Shares will rank pari passu in all respects with the existing issued Ordinary Shares, all having voting rights.

For further enquiries please visit www.beximco-pharma.com or contact:

Beximco Pharma
Nazmul Hassan, MP
Managing Director & CEO
Tel: +880 2 8619151, Ext. 2080

Md. Asad Ullah, FCS, Company Secretary
Tel: +880 2 8618220, Ext.1140

Libertas Capital
Jakob Kinde / Anthony Rowland
Tel: +44 (0)20 7569 9650

Financial Dynamics

Jonathan Birt / Susan Quigley
Tel: +44 (0)20 7269 7169

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.